secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001104659-24-027585
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie issues $15B in senior notes across 7 tranches to fund acquisitions and repay debt
--------------------------------------------------------------------------------

- Issued $15.0B aggregate principal of senior notes maturing 2027-2064 with coupons from 4.800% to 5.500%.
- Proceeds will prepay $5.0B term loan used for ImmunoGen acquisition and fund pending Cerevel acquisition.
- Notes are unsecured, unsubordinated obligations ranking equally with existing unsecured indebtedness.
- Underwriters include Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000110465924027585/0001104659-24-027585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000110465924027585/tm246405d5_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-027585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer